ArticleRheumatology international2025
Determinants and clinical correlates of minor salivary gland biopsy findings for suspected Sjögren disease: a single center retrospective analysis.
Article in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patterns of referral and histopathological interpretation of minor salivary gland biopsy in suspected Sjögren's disease: a single-center experience.Rheumatology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the clinical and pathological characteristics of patients who underwent minor salivary gland biopsy (mSGB) for suspected Sjögren disease (SjD). A total of one hundred five patients who underwent mSGB at a tertiary rheumatology center over a two-year period were included in the study. Demographic and disease characteristics of patients were recorded from electronic health records. The histopathological evaluation of the mSG was performed according to focus score (FS). The ESSDAI and ESSPRI scores were used for disease activity. The study data were analyzed by dividing patients into groups according to whether they met the SjD Classification Criteria and had focal lymphocytic sialadenitis (FLS). The median symptom duration of patients was 28.0 (8-102) months, and 68.5% (72; 105) of them met the SjD Classification Criteria before biopsy. 11.1% of SjD patients (8; 72) had also overlap syndrome. The number of patients with FS ≥ 1 (42, 58.33% vs. 11, 33.33%; p < 0.001), ESSDAI (4.21 ± 2.23 vs. 3.64 ± 2.12; p = 0.023), and ESSPRI-dryness scores (5.12 ± 1.51 vs. 4.72 ± 1.54; p = 0.018) were significantly higher in patients who met the SjD classification criteria than in patients who did not meet the criteria. According to histopathology findings, xerostomia (86.7% vs. 75.0%; p = 0.012), xerophthalmia (75.4% vs. 63.5%; p = 0.024), fatigue (54.7% vs. 42.3%; p = 0.035), ANA (81.1% vs. 69.2%; p < 0.001), SSA (35.8% vs. 26.9%; p = 0.041), and SSB (18.8% vs. 13.4%; p = 0.047) positivity rates were significantly higher in FLS positive (FS ≥ 1) group than the negative group (FS < 1). The unstimulated whole saliva flow [OR (95% CI) = 2.58 (0.94-7.02)] and Schirmer's test [OR (95% CI) = 2.89 (1.04-7.97)] were identified as predictors of FS. This study demonstrated that, whereas diagnostic biopsy findings are predominantly observed in seropositive patients and/or meeting the criteria, FLS positivity is relatively frequent in seronegative individuals who do not fulfill SjD classification criteria. The present study also represented that objective measurements of the sicca symptoms predict FLS.
Indexed as
Identifiers
41359062What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.